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ABSTRACT
The p53 protein can adopt several conformations in cells—“latent,” “active,” or mutant—depending on cel-
lular stress or mutations of the TP53 gene. Today, only a few antibodies discriminating these conformations
are available. We produced three new anti-p53 monoclonal antibodies (MAbs) directed against epitopes of
human p53. The H53C1 MAb recognizes an epitope located at the N-terminal part of the central region of
p53 and can discriminate mutant from wild-type conformation. The H53C2 and H53C3 MAbs are against
different epitopes within the proline-rich region of p53. Moreover, the H53C2 epitope is located in the second
negative regulatory domain of p53 between residues 80 and 93. These MAbs can be used as new tools to study
and modulate the cellular functions of p53.
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INTRODUCTION
TP53 IS A TUMOR SUPPRESSOR GENE, which displays struc-tural and functional alterations in more than 50% of human
cancers.(1) The wild-type p53 protein, a transcription factor, is
known for its ability to induce growth arrest and/or apoptosis
after exposure of cells to stress. After DNA damage, the loss
of a functional p53, as in many tumor cells, authorizes cell pro-
liferation or cell survival without repair of DNA lesions, greatly
contributing to tumor progression. The cell cycle arresting ac-
tivity of p53 is mainly mediated by transcriptional activation of
p21WAF1/cip1 gene expression. The p21WAF1/cip1 protein inhibits
cyclin-dependent kinase 2/cyclin E activity leading to a G1 ar-
rest.(2) p53-dependent apoptosis may be mediated by transcrip-
tional activation of various genes including BAX, but p53 may
also induce apoptosis without transcriptional activation.(3–5)
Several functional domains have been characterized in the
p53 protein. The amino acid residues 1–40 correspond to the
transactivation domain which binds to TFIID.(6,7) The core do-
main (residues 102–292) is the specific DNA binding domain
of p53. It contains four out of the five evolutionary conserved
domains of p53 and has been crystallized.(8–10) Most of the p53
gene alterations found in human cancers is missense mutations
located in this core region. Three domains are related to the
regulation of this transactivation activity. Residues 319–360
correspond to an oligomerization domain necessary for the tran-
scriptional activity.(11) Two domains are involved in the nega-
tive regulation of specific DNA binding: one of these regions
is located between amino acids 80 and 94,(12) the other one is
within the C-terminus, between residues 364 and 393.(13,14) Fi-
nally, a proline-rich region (residues 63–85) is associated to
transcription-independent growth suppression by p53.(15–17)
The use of antibodies recognizing specific regions of p53
greatly helped to characterize the structure/function relationship
of the protein. For example, MAbs binding to the core region
of p53, such as PAb 240 (epitope 213–217), which can distin-
guish mutant from wild-type p53 by immunoprecipitation, con-
tributed to the understanding of the importance of the confor-
mational state p53 activity.(18–20) The ability of the MAb PAb
421 (epitope 371–380) to activate p53 transcriptional activity
demonstrated that the C-terminal region of p53 is a negative
regulatory domain.(13,14) The use of scFv derived from the DO1
MAb revealed the implication of the N-terminal region in the
stability of the p53 protein.(21)
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The core region is hydrophobic and poorly immunogenic.
Indeed, most antisera from patients with tumors expressing mu-
tant p53 and most MAbs produced towards the whole protein
recognize epitopes located in the N- and C- terminal regions of
p53.(22) So far, only few MAbs recognizing epitopes located in
core region were generated, some of them distinguish poten-
tially active from inactive forms of p53 by immunoprecipita-
tion.(18–20)
In this context, generation of MAbs recognizing epitopes in
human p53 core region could help to further characterize the
functional properties of different p53 structural domains. Fur-
thermore, until now, only two mAbs have been described that
recognize the proline-rich region spanning the residues 64–92;
a region shown to be involved in the transmission of anti-pro-
liferative signals(15,16) and in negative regulation of the tran-
scriptional activity of p53 (amino acids 80–93).(12)
The aim of this study was to produce new monoclonal anti-
bodies (MAbs), specific for the proline-rich and the DNA bind-
ing domains. A truncated recombinant p53, including residues
72–308, was used as immunogen. Three MAbs were selected.
Two of them recognize different motifs in the proline-rich re-
gion of p53. The other one binds the N-terminal part of the core
domain and appears to be specific of the p53 conformation.
MATERIALS AND METHODS
Cell lines
MCF7, HepG2, HBL100, BT20, T47D, Huh7, Mahlavu, and
Hep3B cell lines were from ATCC and maintained as de-
scribed.(23) The 3B143, 3B248, and 3B249 cell lines were ob-
tained following transfection of Hep3B cells with pC53-143A,
pC53-248W, and pC53-249R, respectively, and selection with
geneticine.(23)
Production of p53-derived fusion proteins
Recombinant p53 proteins were produced through the 6–His-
tidine QIA express system (Qiagene, Coger, France) using pQE
30 and pQE 32 as vectors. RT-PCR produced cDNA fragments
corresponding to full size or truncated p53 mRNAs were cloned
in frame downstream a 6His-tag between BamH1 and Hind III
restriction sites. Expression in E. coli and purification of pro-
teins were carried out following manufacturer’s instructions. A
truncated p53 protein corresponding to amino acids 72–308 of
p53 was produced using pQE30 as vector and named 6H-Cp53.
Monoclonal antibodies
Purified 6His-central P53 protein (6H-Cp53) was injected
into 6-week-old BALB/c mice. Spleen lymphocytes from a hy-
perimmune animal were fused to SP2/O myeloma in presence
of polyethylene glycol. Hybridomas were selected in hypoxan-
thine/ aminopterin/thymidine medium. Specific antibody se-
cretion was checked by indirect RIA using central (6H-Cp53)
and total (6H-p53) p53 6His fused proteins as antigen and 125I-
labelled goat anti-mouse immunoglobulins as secondary probe.
Hybridomas were cloned by limiting dilution.(24)
Commercially available PAb 240(25) and PAb1801(26) from
Oncoscience (TEBU, France) were used as control antibodies.
Pepscan ELISA analysis
These analyses have been performed as previously de-
scribed.(27) Briefly, 77 biotinilated 15-mer peptides overlapping
each other by 10 residues and spanning p53 were produced.
Each peptide was deposited in a streptavidin precoated well of
microtiter plates. After washing, hybridoma supernatants were
incubated and the presence of specific antibodies was revealed
using a horseradish peroxydase-coupled sheep secondary anti-
body and Orthophenylene diamine (OPD).
Immunoprecipitation
For metabolic labeling, 70% confluent cells were deprived
of serum and methionine for 2 h prior a 4-h incubation in the
presence of [35S]-methionine (200 Ci/mL). Cells were then
washed with PBS and lysed in lysis buffer (50 mM Tris pH7.4,
25 mM NaCl, 1 mM CaCl2, and 50 mM NaF) with a cocktail
of protease inhibitor (PIC) containing PMSF (50 g/mL), 
Leupeptin (1 g/mL), Soybean Trypsin Inhibitor (10 g/mL),
Aprotinin (1 g/mL) and TPCK (10 g/mL) for 20 min at 4°C.
Cell extracts were then centrifuged for 15 min at 4°C and su-
pernatant pre-cleared 1 h with protein A. Incubation with spe-
cific mAbs was carried out overnight at 4°C with gentle shak-
ing. The immune complexes were precipitated with 80 L of
Protein A-sepharose beads for 1-h incubation. After four washes
with lysis buffer, the immune complexes were separated by
SDS-PAGE. Dried gels were exposed to autoradiography.
RESULTS
In order to obtain mAbs specific for human p53 core and
proline-rich regions, a histidine-tagged truncated protein corre-
sponding to amino acids 72–308 of p53 was produced in E.
coli. Affinity-purified recombinant p53 protein was then used
as immunogen to generate mouse mAbs. Fusion experiments
were performed as previously described(24) and hybridoma su-
pernatants tested by solid-phase radioimmunoassay (RIA). As
observed by other groups,(19,20) fusion yields were lower than
those observed using immunogens containing the N-terminal
region of the p53 protein, as only 25 of 525 hybridoma super-
natants displayed strong immunogenicity to the immunogen
(data not shown). We performed a further selection by RIA
against recombinant full-size and truncated p53 proteins. Su-
pernatants were also tested for their ability to recognize 
p53 from cells by western-blot and immuno-cytochemistry
(Table 1).
After this further selection, six clone supernatants were tested
for epitope definition by a PEPSCAN ELISA technique de-
scribed by Legros et al.(27) As presented in Table 1, the H53C1
MAb recognized five residues from Tyr126 to Leu130. This
epitope is located in the core domain within the second highly
conserved region of p53, as indicated in Figure 1. Two other
mAbs recognized epitopes in the region flanking the core do-
main of p53: H53C2, binding p53 between Ala86 and Ser95
and H53C3, between Ala76 and Pro80. As shown in Figure 1,
these epitopes are located in the proline-rich region described
by Walker and Levine and match different proline (P-X-X-P)
motifs.(15) The epitope of H53C2 also partially covers the neg-













































Three other antibodies H53C4, C8 and C9, recognized an epi-
tope located between Arg181 and Pro190 which is recognized
by previously described MAbs. Hybridomas producing anti-
bodies H53C1, H53C2, and H53C3 were cloned twice by lim-
ited dilution and their epitopes confirmed.
In order to determine the specificity of these three MAbs for
wild-type and mutant conformations of p53, we performed im-
munoprecipitations under non-denaturing conditions using ex-
tracts from human cell lines expressing either wild-type or mu-
tant p53 proteins. MAb PAb1801 was used as a reference for
all conformations and PAb 240 for its specificity towards the
mutant form of p53. Immunoprecipitations performed using the
hybridoma H53C1 cells revealed that it is able to distinguish
different conformations of p53 (Fig. 2 and Table 2). Indeed, it
precipitated most of the mutant p53 proteins tested, but not the
wild-type form of the protein. These observations suggest that
the epitope recognized by H53C1 is not available for antibody
binding in the wild-type conformation. Surprisingly, this anti-
body recognized three bands in Huh7 cell extracts, but none of
them corresponded to the expected size for p53 (Fig. 2).
In contrast to H53C1, the H53C2 MAb recognizes both wild-
type and mutant forms of p53 (Fig. 2 and Table 2). Two other
previously described MAbs (HO15-4 and HO16-4) binding the
same epitope have been shown to selectively recognize the mu-
tant p53 conformation by immunoprecipitation.(19) The third
MAb (H53C3) could immunoprecipitate all tested forms of p53,
although its binding affinity appeared to be weaker than that of
H53C2.
DISCUSSION
The aim of this study was to produce new MAbs specific for
p53 regions for which there is a limited number of available
antibodies, namely proline-rich and DNA-binding domains.
The amino- and carboxy-terminal regions of p53 are highly im-
munogenic, and it is not likely to obtain antibodies against the
less immunogenic proline-rich and core domains using native
p53 as immunogen. Therefore, we decided to produce a trun-
cated p53 recombinant protein corresponding to amino acids
72–308 and to use it as immunogen. Early during the antibody
selection, we determined the epitope of six antibodies out of
nine by PEPSCAN-ELISA. Three (H53 C4, C8, and C9) rec-
ognized the same epitope within the L2 loop of the core do-
main, an epitope for which several MAbs have been previously
described: HO3-5, HO31-1,(19) and DO11.(20) This observation
suggests that this portion is more immunogenic than other parts
of the p53 core domain, consistent with the external position of
this L2 loop determined through crystallography studies.(8)
Another antibody, H53C1, bound an epitope located in the
second highly evolutionary conserved domain of p53. Interest-
ingly, not much is known concerning the immunogenicity of
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TABLE 1. CHARACTERISTICS OF ANTIBODIES OBTAINED AFTER IMMUNIZATION
WITH A RECOMBINANT TRUNCATED P53 PROTEIN (72–308)
ELISA
MAbs Isotype Epitope 6H-Cp53 WB IP IC
H53C1 IgG1 126-YSPAL-130    
H53C2 IgG1 86-APAPSWPLSS-95    
H53C3 IgG1 76-APAAP-80    
H53C4 IgM 181-RCSDSDGLAP-190   ND ND
H53C8 IgG3 181-RCSDSDGLAP-190   ND ND
H53C9 IgG1 181-RCSDSDGLAP-190   ND ND
Epitopes were determined using PEPSCAN analysis as described by Legros et al.26 ELISA was performed on the central part
of p53 protein (6H-Cp53). WB (Westen Blot) and IC (ImmunoCytochemistry) were performed on p53 transfected cells.
FIG. 1. Localization of the epitopes recognized by H53C1, H53C2, and H53C3 on p53 amino acid sequence. Black bars, epi-
tope location; underlined sequences, PXXP proline rich motifs (A–E)(15); plain region, negative regulating domain(12); gray box,












































this domain, for which no antibody has been described. The
analysis of missense mutations pattern observed in human can-
cer cells reveals that this region is rarely targeted for somatic
mutations. However, mutations of this region were associated
with a poor prognosis in breast and lung tumors.(28,29) Struc-
turally, this domain corresponds to the Sheet Loop Helix mo-
tif that contributes to the folding of the p53 protein by bring-
ing together distant residues (Lys120 and Arg283) to form a
specific DNA-binding motif.(8) This suggests that this region is
crucial for the protein conformation. The fact that H53C1 can
distinguish mutant from wild-type p53 confirms the structure
data. As this antibody displays a better affinity for mutant p53
proteins, its epitope may not be accessible in the native con-
formation necessary for DNA-binding. Also, the high degree of
conservation suggests that it could bear an unknown specific
function of p53. A tool such as H53C1 MAb may help to bet-
ter understand specific functions of this region.
Until recent studies, no particular function was attributed to
the region of p53 located between the transactivation and the
core domains. However, the analyses by enzymatic digestions
indicated that a domain between amino acids 68 and 96 was re-
sistant to proteolysis by subtilisin, suggesting that it could play
a role in p53 stability.(9) Indeed, in this region, two overlapping
domains have been defined to drive different activities. First,
VOELTZEL ET AL.290
TABLE 2. SUMMARY OF THE IMMUNOREACTIVITY OF NEW ANTI-P53 MONOCLONAL ANTIBODIES WITH
WILD-TYPE AND MUTANT P53 PROTEINS AS TESTED BY IMMUNOPRECIPITATION
AFTER METABOLIC LABELING OF DIFFERENT CELL LINES BY [35S]-METHIONINE
Cell lines p53 status PAb 1801 PAb 240 H53 C1 H53 C2 H53 C3
MCF7 WT     
HepG2 WT     
HBL100 WTTAg     
BT20 K132Q     
T47D L194F     
Huh7 Y220C     
Mahlavu A249S     
Hep3B Null     
3B143 V143A     
3B248 R248W     
3B249 R249S ND ND   
FIG. 2. Immunoprecipitation of wild-type (MCF7) or mutant (BT 20, Huh7, T47D, Mahlavu) endogenous p53 from various













































Walker and Levine have shown that the proline-rich region
which contains several P-X-X-P motifs between residues 63 and
85 (Fig. 1) was involved in the transmission of antiprolifera-
tive signals.(15) Secondly, Muller-Tieman et al. have reported
that residues 86–93 could be involved in the negative regula-
tion of specific DNA-binding of p53.(12) Previous studies have
suggested that the C-terminal negative regulatory domain
(330–393) could inhibit DNA-binding of p53 through an inter-
action with the core domain.(30–32) Muller-Tieman et al. have
determined that amino acids 80–93 were necessary for this in-
teraction and that corresponding synthetic peptides could acti-
vate the p53 specific DNA-binding activity. This region may
then be involved in the regulation of the p53 conformation and
conformation-dependent activities.(12)
The proline-rich region is fairly conserved among mam-
malians,(33) and proline motifs (P-X-X-P) are present at least
as one copy in all the referred mammalian p53 proteins as well
as in the p53 homologues p63 and p73 protein (34). We ob-
tained two MAbs recognizing sequences located in this region:
H53C2 and H53C3. The MAb H53C3 precisely binds the third
proline motif (P-A-A-P) of human p53, five residues upstream
the H53C2 epitope, which encompasses the fifth Proline motif
(P-S-W-P) (Fig. 1). These two MAbs may be helpful in study-
ing this proline-rich domain and better defining the relative im-
plication of these two motifs in p53 conformation and activity.
Furthermore, the epitope defined by PEPSCAN analysis for
H53C2 is within a 10–amino-acid sequence located at the fron-
tier between the proline-rich region described by Walker et al.
and the core domain.(15) As shown in Figure 1, this sequence
also corresponds to the negative regulatory domain described
by Muller-Tiemann et al.(12) The location of this epitope sug-
gests that H53C2 could help to study the central negative reg-
ulatory region of p53 and that it could be able to modulate the
DNA-binding activity of p53, as PAb421 does through its bind-
ing to the C-terminal negative regulation domain.(13,39)
In other respects, it is also worthwhile to point out that the
H53C2 epitope is located near the interaction domain of p53
with inactive JNK at residues 97–116, while active JNK phos-
phorylates p53 on threonine 81, just beside the H53C3 epi-
tope.(40) These two MAbs could then be very useful for study-
ing JNK-related regulation of p53.
In conclusion, p53-specific MAbs are used for many pur-
poses, from the characterization of functional or regulatory do-
mains to therapeutic strategies.(41–44) The three MAbs described
here (H53C1, H53C2, and H53C3) offer new opportunities for
such strategies, since they bind new epitopes within regions im-
portant for p53 activities. H53C1 could help study mutations
affecting the core domain. H53C1 and H53C2 may provide ad-
ditional tools for studying modulation of DNA binding activ-
ity. H53C2 and H53C3 could be useful in analyzing the regu-
lation by the proline-rich region as well as the JNK interaction
and phosphorylation, on the p53 activity.
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